Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

In a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achie...

Full description

Saved in:
Bibliographic Details
Main Authors: Klemens Budde, Thomas Rath, Volker Kliem
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Journal of Transplantation
Online Access:http://dx.doi.org/10.1155/2014/179705
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551632000253952
author Klemens Budde
Thomas Rath
Volker Kliem
author_facet Klemens Budde
Thomas Rath
Volker Kliem
author_sort Klemens Budde
collection DOAJ
description In a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achieving a hemoglobin level of 11-12 g/dL at each of visits between months 7 and 9. At study entry, 224 patients (80.3%) were receiving erythropoiesis stimulating agent (ESA) therapy including darbepoetin alfa (98), epoetin beta (61), and C.E.R.A. (45). The mean (SD) time between C.E.R.A. applications was 34.0 (11.9) days. Among 193 patients for whom efficacy data were available, mean (SD) hemoglobin was 11.1 (0.99) g/dL at study entry, 11.5 (1.1) g/dL at month 7, 11.6 (1.3) g/dL at month 9, and 11.4 (1.1) g/dL at month 15. During months 7–9, 20.7% of patients had all hemoglobin values within the range 11-12 g/dL and 64.8% were within 10–13 g/dL. Seven patients (2.5%) discontinued C.E.R.A. due to adverse events or serious adverse events. In this observational trial under real-life conditions, once-monthly C.E.R.A. therapy achieved stable hemoglobin levels in stable kidney transplant recipients with good tolerability, and with no requirement for any dose change in 43% of patients.
format Article
id doaj-art-cdc7feaf86824c33acd8aca2048c08f5
institution Kabale University
issn 2090-0007
2090-0015
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Journal of Transplantation
spelling doaj-art-cdc7feaf86824c33acd8aca2048c08f52025-02-03T06:01:06ZengWileyJournal of Transplantation2090-00072090-00152014-01-01201410.1155/2014/179705179705Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational StudyKlemens Budde0Thomas Rath1Volker Kliem2Department of Nephrology, Charité, Medical University, 10117 Berlin, GermanyDepartment of Nephrology and Transplantation Medicine, Westpfalz Hospital, 67655 Kaiserslautern, GermanyNephrology Center of Lower Saxony and Transplant Center, Vogelsang 105, 34346 Hann. Münden, GermanyIn a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achieving a hemoglobin level of 11-12 g/dL at each of visits between months 7 and 9. At study entry, 224 patients (80.3%) were receiving erythropoiesis stimulating agent (ESA) therapy including darbepoetin alfa (98), epoetin beta (61), and C.E.R.A. (45). The mean (SD) time between C.E.R.A. applications was 34.0 (11.9) days. Among 193 patients for whom efficacy data were available, mean (SD) hemoglobin was 11.1 (0.99) g/dL at study entry, 11.5 (1.1) g/dL at month 7, 11.6 (1.3) g/dL at month 9, and 11.4 (1.1) g/dL at month 15. During months 7–9, 20.7% of patients had all hemoglobin values within the range 11-12 g/dL and 64.8% were within 10–13 g/dL. Seven patients (2.5%) discontinued C.E.R.A. due to adverse events or serious adverse events. In this observational trial under real-life conditions, once-monthly C.E.R.A. therapy achieved stable hemoglobin levels in stable kidney transplant recipients with good tolerability, and with no requirement for any dose change in 43% of patients.http://dx.doi.org/10.1155/2014/179705
spellingShingle Klemens Budde
Thomas Rath
Volker Kliem
Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
Journal of Transplantation
title Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
title_full Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
title_fullStr Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
title_full_unstemmed Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
title_short Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
title_sort anemia control in kidney transplant recipients using once monthly continuous erythropoietin receptor activator a prospective observational study
url http://dx.doi.org/10.1155/2014/179705
work_keys_str_mv AT klemensbudde anemiacontrolinkidneytransplantrecipientsusingoncemonthlycontinuouserythropoietinreceptoractivatoraprospectiveobservationalstudy
AT thomasrath anemiacontrolinkidneytransplantrecipientsusingoncemonthlycontinuouserythropoietinreceptoractivatoraprospectiveobservationalstudy
AT volkerkliem anemiacontrolinkidneytransplantrecipientsusingoncemonthlycontinuouserythropoietinreceptoractivatoraprospectiveobservationalstudy